Johnson & Johnson (JNJ)
Summary
JNJ Chart
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa. , June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG).
Johnson & Johnson Dividends
| JNJ 3 weeks ago | Other | €1.13 Per Share |
| JNJ 4 months ago | Other | €1.08 Per Share |
| JNJ 6 months ago | Other | €1.08 Per Share |
| JNJ 9 months ago | Other | €1.08 Per Share |
| JNJ 20 May 2024 | Other | €1.08 Per Share |
Johnson & Johnson Earnings
| 16 Jul 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
| JNJ 3 weeks ago | Other | €1.13 Per Share |
| JNJ 4 months ago | Other | €1.08 Per Share |
| JNJ 6 months ago | Other | €1.08 Per Share |
| JNJ 9 months ago | Other | €1.08 Per Share |
| JNJ 20 May 2024 | Other | €1.08 Per Share |
| 16 Jul 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Joaquin Duato CEO | XMUN Exchange | US4781601046 ISIN |
| US Country | 138,100 Employees | 18 Feb 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
Contact Information
